Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2004-03-08
2008-08-05
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S325000, C435S252300, C536S023400
Reexamination Certificate
active
07407777
ABSTRACT:
Compounds, genetic constructs, and cancer treatment methods are provided. Expression vectors were designed to express fusion genes including hIL-2 with a Fcε-γ transmembrane anchor derived from a subunit of the FC epsilon receptor. mRNA and the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by microscopy. RD995 cells transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into C3H/HEN mice. Tumors of mice implanted with 106or 105RD995 cells transfected with IL-2tm grew slower than controls. It is believed that selective expression of cytokines such as IL-2 on the surface of tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition and killing, potentially avoiding toxicity associated with known cytokine therapies.
REFERENCES:
patent: 5641665 (1997-06-01), Hobart
Vanderspek et al. “Structure/Function Analysis of the Transmembrane Domain of DAB389- Interluekin-2, an Interluekin-2 Receptor-targeted Fusion Toxin.” The Journal of Biological Chemistry, Jun. 1993, vol. 268, No. 16, pp. 12077-12082, especially pp. 12077-12078.
Belani R, Weiner GJ. Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells. Immunology. Feb. 1996;87(2):271-4.
Eckenberg R, Rose T, Moreau JL, Weil R, Gesbert F, Dubois S, Tello D, Bossus M, Gras H, Tartar A, Bertoglio J, Chouaïb S, Goldberg M, Jacques Y, Alzari PM, Thèze J. The first alpha helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor beta chain, and induces lymphokine-activated killer cells. J Exp Med. Feb. 7, 2000;191(3):529-40.
El-Shami et al, Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. Inteferon and Cytokine Res.. 19:1391-1401 (1999).
Emtage et al., A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model, J. Immuno., 160: 2531-2538 (1998).
Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J. Sci. Am., 3 (1997) S70-S72.
Grimm & Wilson, The human lymphokine-activated killer system. . . . blood lymphocytes, Cell Immunol., 94: 568-578 (1985).
Herblot S, Chastagner P, Samady L, Moreau JL, Demaison C, Froussard P, Liu X, Bonnet J, Thèze J. IL-2-dependent expression of genes involved in cytoskeleton organization, oncogene regulation, and transcriptional control. J Immunol. Mar. 15, 1999;162(6):3280-8.
Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol. Dec. 15, 1999;163(12):6378-85.
Kurzrock, Cytokine: Interleukins and Their Receptors. Massachusetts: Kluwer Academic Publishers, 83-97. (1995).
Legha SS. 1997 Durable complete responses in metastatic melanoma treated with Interleukin-2 in combination with Interferon Alfa and Chemotherapy. Sem Oncol 24 ((2)) (S4-39-S4-43).
Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther. Jan. 2000;7(1):31-4.
Luo et al., Comparison of the Effects of Immunosuppressive Factors from Newly Established Colon Carcinoma Cell Cultures on Human Lymphocyte Proliferation and Cytokine Secretion, Tumor Biol., 21:11-20. (1999).
Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. Nov. 1997;4(11):1181-8.
Mertelsmann R,Welte K. Human Interleukin 2: molecular biology, physiology and clinical possibilities. Immunobiol.1986;172:400-19.
Rochlitz et al., Gene Therapy Study of Cytokine-Transfected Xenogeneic Cells (†Vera-interleukin-2) in Patients with Metastatic Solid Tumors, Cancer Gene Therapy, 6:271-281, (1999).
Rosenberg, SA, BS Packard, PM Aebersold, D Solomon, SL Topalian, ST Toy, P Simon, MT Lotze, JC Yang, CA Seipp, and et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report (1988) New England Journal of Medicine vol. 319:1676-1680.
Schneeberger, et al, The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role., J. Immunol. 162:6650-6657. (1999).
Siegel& Puri, Interleukin-2 toxicity, .J Clin. Oncol, 9: 694-704 (1991).
Topalian et al., Tumor-specific cytolysis by lymphocytes infiltrating human melanomas, J. Immunol, 142:3714. (1989).
Vanderspek, J. et al, “DAB-389 interleukin-2 receptor binding domain mutations: Cytotoxic probes for studies of ligand-receptor interactions” Journal Biological Chemistry vol. 271 No. 21, pp. 12145-12149, (1996).
Vile RG, Russell SJ, Lemoine NR. Gene Ther. Cancer gene therapy: hard lessons and new courses. Jan. 2000;7(1):2-8.
Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. Mar. 1, 1999;93(5):1612-21.
Adams Nathan Bradley
McGregor John
Samlowski Wolfram
McCallum Esq. Jennifer M.
Mertz Prema
The McCallum Law Firm, P.C.
University of Utah Research Foundation
LandOfFree
IL-2 transmembrane construct does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-2 transmembrane construct, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-2 transmembrane construct will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4007461